Table 4.
Univariate and multivariate Cox proportional hazard regression analyses of OS.
| Parameter | Cutoff | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Age (years) | Continuous | 1.02 (1.00–1.05) per score | 0.05 | ||
| Sex | Male | Reference | 0.90 | ||
| Female | 0.97 (0.58–1.62) | ||||
| ECOG PS | ≤ 1 | Reference | < 0.01* | Reference | < 0.01* |
| ≥ 2 | 5.64 (3.23–9.83) | 3.53 (1.85–6.74) | |||
| Primary site | Bladder | Reference | < 0.05* | Reference | 0.12 |
| Upper tract or both | 1.63 (1.04–2.57) | 1.44 (0.90–2.28) | |||
| Resection of primary site | No | Reference | 0.60 | ||
| Yes | 0.87 (0.53–1.44) | ||||
| Lymph node metastasis | No | Reference | 0.12 | ||
| Yes | 1.44 (0.91–2.29) | ||||
| Lung metastasis | No | Reference | 0.58 | ||
| Yes | 1.14 (0.73–1.77) | ||||
| Bone metastasis | No | Reference | 0.05 | ||
| Yes | 1.71 (0.99–2.95) | ||||
| Liver metastasis | No | Reference | < 0.01* | Reference | 0.08 |
| Yes | 2.59 (1.57–4.27) | 1.65 (0.94–2.90) | |||
| No. of prior regimens | 1 | Reference | 0.52 | ||
| ≥ 2 | 1.18 (0.72–1.94) | ||||
| AGR | ≥ 0.95 | Reference | < 0.01* | Reference | < 0.01* |
| < 0.95 | 3.18 (1.98–5.09) | 2.60 (1.48–4.59) | |||
| NLR | < 3 | Reference | < 0.01* | Reference | 0.37 |
| ≥ 3 | 1.95 (1.19–3.18) | 1.28 (0.75–2.19) | |||
| Hemoglobin (g/dL) | < LLN† | Reference | 0.07 | ||
| ≥ LLN† | 0.54 (0.28–1.04) | ||||
| eGFR (mL/min/1.73 m2) | < 60 | Reference | 0.72 | ||
| ≥ 60 | 0.92 (0.56–1.49) | ||||
| C-reactive protein (mg/dL) | < 0.5 | Reference | < 0.01* | Reference | 0.57 |
| ≥ 0.5 | 2.04 (1.28–3.23) | 1.17 (0.67–2.05) | |||
AGR albumin-to-globulin ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group Performance Status, eGFR estimated glomerular filtration rate, HR hazard ratio, LLN lower limit of normal, NLR neutrophil-to-lymphocyte ratio, OS overall survival.
†LLN of hemoglobin was set at 13.0 g/dL for men and 11.5 g/dL for women.
*Statistically significant.